Investment Thesis
While QHSLab demonstrates strong gross margins (67.3%) and revenue growth (+26.3% YoY), critical financial red flags undermine credibility: interest coverage of 0.6x indicates operating income cannot service debt obligations, and a substantial gap between net income ($457.4K) and operating cash flow ($178.1K) signals significant earnings quality concerns. The microscopic revenue base ($2.7M) compounds volatility and sustainability risks.
Strengths
- Exceptional gross margin of 67.3% indicates strong product positioning and pricing power in medical instruments
- Solid top-line revenue growth of 26.3% YoY demonstrates market demand
- Conservative capital structure with minimal leverage (Debt/Equity 0.06x) reduces financial distress risk
Risks
- Critical interest coverage ratio of 0.6x means operating income cannot cover interest expenses, indicating refinancing dependency
- Severe earnings quality deterioration: net income growth of 276% not supported by operating cash flow growth, suggesting non-cash gains or accounting anomalies
- Microscopic scale ($2.7M revenue) creates severe operational fragility and revenue concentration risks
Key Metrics to Watch
- Interest Coverage Ratio trending back above 1.0x (currently unsustainable at 0.6x)
- Operating Cash Flow convergence with Net Income (currently 61% gap suggests quality issues)
- Revenue growth sustainability beyond current 26.3% YoY pace
Financial Metrics
Revenue
2.7M
Net Income
457.4K
EPS (Diluted)
$0.02
Free Cash Flow
178.1K
Total Assets
2.2M
Cash
636.2K
Profitability Ratios
Gross Margin
67.3%
Operating Margin
4.9%
Net Margin
17.0%
ROE
28.1%
ROA
21.1%
FCF Margin
6.6%
Balance Sheet & Liquidity
Current Ratio
1.96x
Quick Ratio
1.88x
Debt/Equity
0.06x
Debt/Assets
25.2%
Interest Coverage
0.55x
Long-term Debt
90.7K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T08:06:24.107614 |
Data as of: 2025-12-31 |
Powered by Claude AI